Solid Biosciences Inc. (SLDB): Price and Financial Metrics
SLDB Price/Volume Stats
| Current price | $6.25 | 52-week high | $14.25 |
| Prev. close | $6.29 | 52-week low | $3.40 |
| Day low | $6.25 | Volume | 350 |
| Day high | $6.25 | Avg. volume | 31,300 |
| 50-day MA | $5.34 | Dividend yield | N/A |
| 200-day MA | $6.61 | Market Cap | 122.51M |
SLDB Stock Price Chart Interactive Chart >
SLDB POWR Grades
- Sentiment is the dimension where SLDB ranks best; there it ranks ahead of 89.18% of US stocks.
- SLDB's strongest trending metric is Value; it's been moving down over the last 179 days.
- SLDB's current lowest rank is in the Quality metric (where it is better than 20.75% of US stocks).
SLDB Stock Summary
- SLDB's price/sales ratio is 19.1; that's higher than the P/S ratio of 93.98% of US stocks.
- With a year-over-year growth in debt of 1,721.98%, SOLID BIOSCIENCES INC's debt growth rate surpasses 99.09% of about US stocks.
- Revenue growth over the past 12 months for SOLID BIOSCIENCES INC comes in at -49.48%, a number that bests only 4.92% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to SOLID BIOSCIENCES INC are TCRX, LIFE, FUSN, AUTL, and EVGN.
- Visit SLDB's SEC page to see the company's official filings. To visit the company's web site, go to www.solidbio.com.
SLDB Valuation Summary
- SLDB's price/sales ratio is 19.7; this is 286.27% higher than that of the median Healthcare stock.
- Over the past 65 months, SLDB's price/earnings ratio has gone up 17.9.
Below are key valuation metrics over time for SLDB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SLDB | 2023-05-23 | 19.7 | 0.7 | -1.3 | 0.2 |
| SLDB | 2023-05-22 | 19.3 | 0.6 | -1.3 | 0.2 |
| SLDB | 2023-05-19 | 19.1 | 0.6 | -1.3 | 0.2 |
| SLDB | 2023-05-18 | 19.2 | 0.6 | -1.3 | 0.2 |
| SLDB | 2023-05-17 | 19.5 | 0.7 | -1.3 | 0.2 |
| SLDB | 2023-05-16 | 19.9 | 0.7 | -1.4 | 0.2 |
SLDB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SLDB has a Quality Grade of C, ranking ahead of 48.77% of graded US stocks.
- SLDB's asset turnover comes in at 0.043 -- ranking 329th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SLDB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.043 | 1 | -1.880 |
| 2021-06-30 | 0.036 | 1 | -6.662 |
| 2021-03-31 | 0.024 | 1 | -26.655 |
| 2020-12-31 | 0.000 | NA | -12.889 |
| 2020-09-30 | 0.000 | NA | -8.496 |
| 2020-06-30 | 0.000 | NA | -6.389 |
SLDB Price Target
For more insight on analysts targets of SLDB, see our SLDB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.33 | Average Broker Recommendation | 1.78 (Moderate Buy) |
Solid Biosciences Inc. (SLDB) Company Bio
Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene transfer candidate that is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients’ muscles. The company was formerly known as Solid Ventures, LLC and changed its name to Solid Biosciences, LLC in June 2015. Solid Biosciences, LLC was founded in 2013 and is based in Cambridge, Massachusetts.
Latest SLDB News From Around the Web
Below are the latest news stories about SOLID BIOSCIENCES INC that investors may wish to consider to help them evaluate SLDB as an investment opportunity.
Solid Biosciences to Participate at the Jefferies Healthcare ConferenceCHARLESTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 3:00 PM ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by c |
Solid Biosciences to Participate at the Barclays Gene Editing & Therapy SummitCHARLESTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Gene Editing & Therapy Summit on Wednesday, May 24, 2023 at 11:30 AM ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website |
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting— Oral presentation highlighting data from multiple animal models demonstrated administration of AVB-202 resulted in frataxin (FXN) expression in cardiac and central nervous system (CNS) tissues with a favorable safety profile and may improve cardiac function and extend survival — — Five additional abstracts relating to the company’s next-generation capsid activities, adeno-associated vector manufacturing methods and quality assurance assays to be presented as posters — CHARLESTOWN, Mass., May 1 |
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue EstimatesSolid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.85% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Solid Biosciences Provides First Quarter Business Update and Financial Results– Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Company ends first quarter with approximately $185.5 million in cash and investments; Anticipated cash runway into 2025 – CHARLESTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financial results for |
SLDB Price Returns
| 1-mo | 16.82% |
| 3-mo | 18.15% |
| 6-mo | -3.55% |
| 1-year | -30.56% |
| 3-year | -85.73% |
| 5-year | -98.24% |
| YTD | 16.17% |
| 2022 | -79.50% |
| 2021 | -76.91% |
| 2020 | 70.34% |
| 2019 | -83.40% |
| 2018 | N/A |
Loading social stream, please wait...